# Pharmaceutical Company Partnerships

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Development Officer & Chief Science Officer
**Purpose**: Strategic framework for building mutually beneficial partnerships with pharmaceutical companiesâ€”particularly augmentation therapy manufacturers and gene therapy developersâ€”balancing revenue generation with patient advocacy independence

---

## ğŸ“‹ Table of Contents

1. [Partnership Philosophy](#partnership-philosophy)
2. [Target Companies](#target-companies)
3. [Partnership Models](#partnership-models)
4. [Revenue Opportunities](#revenue-opportunities)
5. [Maintaining Independence](#maintaining-independence)
6. [Contract Negotiation Guidelines](#contract-negotiation-guidelines)
7. [Partnership Activation](#partnership-activation)
8. [Success Metrics](#success-metrics)
9. [Risk Management](#risk-management)
10. [Implementation Timeline](#implementation-timeline)

---

## Partnership Philosophy

### Core Principle: Aligned Interests, Maintained Independence

**The Opportunity**:

- Pharma companies need patient organizations (market access, clinical trial recruitment, disease awarenessâ€”Foundation has patients, credibility, reach)
- Foundation needs pharma (funding for programs, research collaboration, access to therapiesâ€”companies have capital, R&D capacity)

**The Challenge**:

- Perceived conflicts (patients worry Foundation becomes "pharma puppet"â€”lose trust if seen as industry-funded)
- Actual conflicts (what if Foundation must advocate against company interest?â€”e.g., drug pricing, insurance coverage)

**Foundation's Approach**:

- âœ… **Strategic partnerships** (not transactionalâ€”long-term relationships with aligned companies)
- âœ… **Transparent funding** (disclose all pharma supportâ€”donors know who funds what)
- âœ… **Diversified revenue** (pharma = 20-30% of budget maxâ€”never over-reliant on single source)
- âœ… **Editorial independence** (companies fund programs, but Foundation controls contentâ€”no veto power on advocacy, education)
- âœ… **Patient-first decisions** (if company interests diverge from patient interestsâ€”Foundation always sides with patients)

---

### Why Pharma Companies Partner with Patient Organizations

**Market Access & Awareness**:

- Increase diagnosis rates (only 10% of AATD patients diagnosedâ€”companies need more patients identified to expand market)
- Educate physicians (primary care doctors don't test for AATDâ€”Foundation educates, testing increases, prescriptions increase)
- Patient support programs (help patients access therapyâ€”Foundation navigation reduces abandonment, improves adherence)

**Clinical Trial Recruitment**:

- Faster enrollment (Foundation registry = trial-ready patientsâ€”cut recruitment time from 2 years to 6 months)
- Better retention (Foundation support = lower dropoutâ€”complete datasets, stronger evidence)

**Corporate Social Responsibility**:

- Genuine mission alignment (pharma employees want to help patientsâ€”Foundation partnership satisfies CSR goals)
- Reputation management (supporting patient advocacy = positive brandâ€”offsets negative perceptions of "greedy pharma")

**Regulatory & Payer Relations**:

- Patient voice (FDA, CMS listen to patientsâ€”Foundation testifies on company's behalf if therapy is effective)
- Real-world evidence (Foundation registry data supplements clinical trialsâ€”payers more likely to cover)

---

## Target Companies

### Tier 1: Augmentation Therapy Manufacturers (Current Market)

**1. Grifols (Prolastin-C)**

- **Market Share**: ~50% of US augmentation market
- **Company Profile**: Spanish pharma, plasma-derived proteins specialty (also makes immunoglobulins, albumin)
- **AATD Commitment**: Long history (30+ years making AAT), significant R&D (improved formulations, clinical trials)
- **Partnership Potential**: HIGH (largest playerâ€”most to gain from diagnosis rate increase, most resources to invest)

**Key Asks to Grifols**:

- Unrestricted educational grant: $500K-$1M/year (fund patient education, support groups, conference)
- Clinical trial collaboration: Co-fund trials (Foundation recruits patients, Grifols funds, both benefit from data)
- Patient assistance: Co-pay support ($2M-$5M/yearâ€”Grifols funds, Foundation administersâ€”helps uninsured/underinsured)

---

**2. CSL Behring (Zemaira)**

- **Market Share**: ~25% of US augmentation market
- **Company Profile**: Australian pharma, plasma-derived proteins (also makes immunoglobulins, hemophilia factors)
- **AATD Commitment**: Strong (invested in augmentation R&D, sponsors conferences, patient registries)
- **Partnership Potential**: HIGH (competitive with Grifolsâ€”eager to differentiate, support Foundation as strategy)

**Key Asks to CSL Behring**:

- Event sponsorship: $250K-$500K/year (sponsor Breathe Easy Walk, Annual Conferenceâ€”brand visibility, patient engagement)
- Research funding: $300K-$500K/year (co-fund Foundation research grantsâ€”CSL gets first look at data, academic goodwill)
- Registry support: $200K/year (fund data infrastructureâ€”CSL gains access to real-world evidence for payer negotiations)

---

**3. Takeda (Glassia)**

- **Market Share**: ~15% of US augmentation market
- **Company Profile**: Japanese pharma (acquired Glassia from Baxter/Baxalta), global reach
- **AATD Commitment**: Moderate (smaller playerâ€”but wants to grow share)
- **Partnership Potential**: MODERATE (less capital than Grifols/CSL, but motivated to competeâ€”may be flexible partner)

**Key Asks to Takeda**:

- Program sponsorship: $150K-$300K/year (fund specific programsâ€”e.g., Patient Navigation, Support Groupsâ€”Takeda brand visible to patients)
- International collaboration: Expand Foundation reach to Japan, Asia (Takeda has strong Asia presenceâ€”help Foundation go global)

---

**4. Kamada (Glassiaâ€”co-markets with Takeda)**

- **Market Share**: Small (Israeli biotechâ€”manufactures Glassia, Takeda distributes in US)
- **Company Profile**: Specialty plasma (focused playerâ€”fewer resources than big 3, but nimble)
- **Partnership Potential**: LOW (limited capitalâ€”but potential for niche collaborations)

**Possible Ask**:

- Research collaboration: $50K-$100K/year (Kamada funds specific researchâ€”e.g., alternative administration methodsâ€”benefits both)

---

### Tier 2: Gene Therapy & Next-Gen Therapeutics (Future Market)

**5. Applied Genetic Technologies Corporation (AGTC) / Asclepix**

- **Pipeline**: AAV-AAT gene therapy (Phase 1/2 trialsâ€”completed 2024)
- **Company Profile**: Small biotech (gene therapy focusâ€”AATD is lead program)
- **Partnership Potential**: HIGH (small companyâ€”needs Foundation for trial recruitment, patient education, advocacy support)

**Key Asks to AGTC/Asclepix**:

- Clinical trial support: $100K-$300K/year (Foundation recruits patients, provides educationâ€”AGTC funds Foundation's trial support program)
- Post-approval planning: Collaborate on access (if approvedâ€”Foundation advocates for insurance coverage, AGTC provides co-pay assistance)

---

**6. Beam Therapeutics**

- **Pipeline**: BEAM-302 (base editing gene therapyâ€”preclinical, IND filing 2025-2026)
- **Company Profile**: CRISPR gene editing biotech (well-fundedâ€”$500M+ cash)
- **Partnership Potential**: MODERATE-HIGH (early stageâ€”but Foundation can help shape development, trial design)

**Key Asks to Beam**:

- Early engagement: $50K-$150K/year (Foundation provides patient input on trial design, education materialsâ€”Beam funds consultation)
- Trial readiness: Registry access (Foundation identifies trial-eligible patientsâ€”Beam enrolls faster)

---

**7. Moderna Therapeutics**

- **Pipeline**: mRNA-AAT (preclinicalâ€”moving toward Phase 1)
- **Company Profile**: mRNA giant (post-COVID, massive resourcesâ€”exploring rare diseases)
- **Partnership Potential**: MODERATE (Moderna has many programsâ€”AATD is small for them, but Foundation can be helpful partner)

**Possible Ask**:

- Research collaboration: $200K-$500K/year (Moderna funds Foundation registry, patient educationâ€”gains patient insights)

---

**8. Vertex Pharmaceuticals**

- **Pipeline**: No AATD program currently (but CF Foundation partnerâ€”could expand to AATD)
- **Company Profile**: CF drug developer (Trikaftaâ€”$6B/year), protein misfolding expert (AATD = similar biology to CF)
- **Partnership Potential**: LOW (no AATD programâ€”but worth tracking, potential future)

**Aspirational**:

- Recruit Vertex to AATD (Foundation pitchesâ€”"AATD is next CF, same biology, we'll support like CF Foundation did"â€”long shot but worth try)

---

### Tier 3: Adjacent Companies (Diagnostics, Devices, Related Therapies)

**9. Invitae, 23andMe, Myriad Genetics (Genetic Testing Companies)**

- **Opportunity**: Partner on genetic testing access (at-home kits, physician testingâ€”see DNA testing simplification document)
- **Partnership**: Co-develop programs ($100K-$300K/yearâ€”companies provide tests at cost, Foundation administers)

**10. Abbott, Roche, Siemens (Diagnostics Companies)**

- **Opportunity**: Develop rapid AAT testing device (see quick AAT testing document)
- **Partnership**: Co-development + licensing (Foundation funds early research [$1M-$3M], companies commercialize, Foundation receives royalties)

---

## Partnership Models

### Model 1: Unrestricted Educational Grant (Preferred)

**Structure**:

- Company provides grant to Foundation (e.g., $500K/year)
- **Unrestricted** (Foundation decides how to use fundsâ€”no strings attached)
- Purpose: Support mission (patient education, support programs, conferencesâ€”broad)

**Benefits to Foundation**:

- âœ… Maximum flexibility (spend on highest prioritiesâ€”staff, programs, research)
- âœ… Editorial independence (company cannot dictate contentâ€”Foundation controls messaging)
- âœ… Simple administration (one check, no reporting burdenâ€”minimal overhead)

**Benefits to Company**:

- âœ… Goodwill (supports patient communityâ€”CSR, brand reputation)
- âœ… Awareness (Foundation's work increases diagnosisâ€”expands market)
- âœ… Tax deduction (charitable contributionâ€”reduces tax burden)

**Terms**:

- Annual renewal (1-year grant, renew each yearâ€”gives both sides flexibility)
- Acknowledgment (Foundation lists company as "Platinum Sponsor"â€”website, materials, events, no endorsement of products)
- Transparency (Foundation discloses grant publiclyâ€”Annual Report, website, Form 990)

**Example**:

- Grifols provides $750K unrestricted grant (2026)
- Foundation uses funds: $300K for Support Group program, $200K for Annual Conference, $150K for Patient Navigation, $100K for general operations
- Foundation acknowledges Grifols: Website ("Platinum Sponsor"), conference program ("Thank you to Grifols for supporting patient programs"), no product endorsement
- Grifols benefits: 2,000 patients attend Foundation programs (learn about AATD, many start augmentation), Grifols brand visible (top-of-mind when patients choose therapy), goodwill in community

---

### Model 2: Program-Specific Sponsorship

**Structure**:

- Company sponsors specific Foundation program (e.g., "Breathe Easy Walk, presented by CSL Behring")
- Grant restricted to that program (Foundation must use funds for designated purposeâ€”e.g., Walk expenses)

**Benefits to Foundation**:

- âœ… Larger sponsorships (companies more comfortable funding visible programsâ€”easier to justify internally)
- âœ… Secure program funding (Walk costs coveredâ€”Foundation can focus other funds on programs without corporate appeal)

**Benefits to Company**:

- âœ… Brand visibility (logo on T-shirts, banners, websiteâ€”direct association with patient event)
- âœ… Employee engagement (company sends employee teams to Walkâ€”team-building, CSR)

**Terms**:

- Multi-year commitment (3-year agreementâ€”predictable for both sides)
- Recognition levels (Presenting $50K, Gold $25K, Silver $10Kâ€”tiered benefits)
- No editorial control (company sponsors event, but Foundation controls contentâ€”no product promotion at event)

**Example**:

- CSL Behring sponsors Breathe Easy Walk ($50K/year, 3 years = $150K)
- Benefits: Logo on T-shirts (1,000 walkers), banner at event, booth at health fair, mentioned in remarks, social media recognition
- CSL Behring sends 50-employee team (company pays registration $2,500, employees fundraise $10Kâ€”total CSL contribution $62.5K)
- Foundation: Walk expenses covered ($50K from sponsorship + $12.5K additional from CSL team), net profit to mission

---

### Model 3: Research Collaboration

**Structure**:

- Company co-funds research with Foundation (e.g., Foundation + Grifols each contribute $250K to real-world outcomes study)
- Shared data (both parties access resultsâ€”Foundation for patient benefit, company for regulatory/payer submissions)

**Benefits to Foundation**:

- âœ… Leverage funding (Foundation's $250K becomes $500K studyâ€”more impact per dollar)
- âœ… Access to company data (companies have proprietary dataâ€”Foundation gains insights)

**Benefits to Company**:

- âœ… Real-world evidence (registry data supplements clinical trialsâ€”supports FDA, payer submissions)
- âœ… Academic credibility (Foundation partnership = neutral, trusted dataâ€”not company-sponsored study)

**Terms**:

- Co-ownership of data (both can publishâ€”academic freedom preserved)
- Publication approval (both parties review manuscriptsâ€”ensure accuracy, not to block publication)
- IP rights (if discovery leads to patentâ€”negotiate split, usually 50/50 or Foundation gets rights)

**Example**:

- Takeda + Foundation co-fund study: "Real-World Outcomes of Augmentation Therapy" ($500K, 2 years, 500 patients from Foundation registry)
- Study shows augmentation slows FEV1 decline, reduces exacerbations, improves QOL (confirms clinical trial data in real-world setting)
- Published in AJRCCM (peer-reviewed, credibleâ€”both Foundation and Takeda co-authors)
- Takeda uses data for payer negotiations ("Real-world study confirms therapy works"â€”insurance coverage improves)
- Foundation uses data for patient education ("Evidence shows augmentation helps"â€”more patients start therapy)

---

### Model 4: Patient Assistance Fund

**Structure**:

- Company funds Foundation's patient assistance program (e.g., Grifols provides $3M/year for co-pay assistance)
- Foundation administers (processes applications, distributes fundsâ€”company not involved in individual decisions)

**Benefits to Foundation**:

- âœ… Help uninsured/underinsured patients (co-pays $5K-$20K/yearâ€”barrier to therapy, Foundation removes barrier)
- âœ… No favoritism (Foundation can assist patients on any brandâ€”Grifols, CSL, Takeda, maintains neutrality)

**Benefits to Company**:

- âœ… Market access (patients who couldn't afford therapy now canâ€”sales increase)
- âœ… Brand loyalty (patients remember "Grifols helped me access therapy"â€”positive association)
- âœ… Regulatory compliance (independent Foundation administersâ€”avoids anti-kickback concerns)

**Terms**:

- Brand-neutral (Foundation can assist patients on any augmentation brandâ€”not just Grifols, avoids conflict)
- Needs-based (Foundation sets eligibility criteriaâ€”income, insurance status, not company)
- Transparency (Foundation reports aggregate dataâ€”# assisted, $ distributed, not individual patient identities)

**Example**:

- Grifols funds Foundation's Co-Pay Assistance Fund ($3M/year)
- Foundation assists 300 patients/year ($10K average co-pay support)
- Patients on Prolastin (Grifols): 150 (50%)
- Patients on Zemaira (CSL): 90 (30%)
- Patients on Glassia (Takeda): 60 (20%)
- Result: Grifols helped all patients (including competitors' patientsâ€”demonstrates industry leadership), sales increase for all brands (patients who couldn't afford therapy now adherent), Foundation fulfills mission (remove financial barriers)

---

## Revenue Opportunities

### 5-Year Revenue Projection from Pharma Partnerships

**Year 1** ($300K-$500Kâ€”pilot partnerships):

- Grifols: $250K unrestricted grant
- CSL Behring: $150K Walk sponsorship
- AGTC: $100K clinical trial support
- **Total**: $500K (25% of $2M budget)

**Year 2** ($600K-$1Mâ€”expand partnerships):

- Grifols: $500K unrestricted
- CSL Behring: $250K (Walk + Conference sponsorship)
- Takeda: $150K program sponsorship
- AGTC: $150K trial support
- Beam: $100K early engagement
- **Total**: $1.15M (29% of $4M budget)

**Year 3** ($1M-$1.5Mâ€”mature partnerships):

- Grifols: $750K (unrestricted + co-pay fund)
- CSL Behring: $400K (events + research)
- Takeda: $200K (programs + research)
- AGTC/Asclepix: $200K (trial + post-approval planning)
- Beam: $150K (trial readiness)
- Moderna: $200K (research collaboration)
- **Total**: $1.9M (32% of $6M budget)

**Year 4-5** ($1.5M-$2.5Mâ€”full portfolio):

- Augmentation manufacturers: $1.5M-$2M (Grifols, CSL, Takedaâ€”combined unrestricted, programs, research, co-pay)
- Gene therapy companies: $500K-$1M (AGTC, Beam, Modernaâ€”trials, access programs)
- Diagnostics: $200K-$500K (Invitae, Abbottâ€”testing programs, device development)
- **Total**: $2.2M-$3.5M (28-35% of $8M-$10M budget)

**Diversification Maintained**: Pharma never exceeds 35% of budget (65%+ from individuals, foundations, eventsâ€”protects independence)

---

### Pharma Revenue by Type

**Year 5 Target Breakdown** ($2.5M total pharma revenue):

- Unrestricted grants: $1M (40%â€”maximum flexibility)
- Program sponsorships: $600K (24%â€”events, patient services)
- Research collaboration: $500K (20%â€”co-funded studies)
- Patient assistance: $400K (16%â€”co-pay support, administered by Foundation)

---

## Maintaining Independence

### Transparency Policy

**Public Disclosure**:

- Annual Report lists all pharma donors ($10K+ disclosedâ€”company name, amount, purpose)
- Website "Our Supporters" page (updated quarterlyâ€”pharma prominently disclosed)
- Form 990 (IRS filing publicâ€”pharma grants visible to anyone)

**Why Transparency Matters**:

- Trust (patients know who funds Foundationâ€”no hidden conflicts)
- Accountability (public scrutiny ensures Foundation stays patient-focusedâ€”can't become pharma puppet)

---

### Editorial Independence

**Non-Negotiable Rules**:

1. **No product endorsements** (Foundation never says "Use Prolastin" or "Zemaira is best"â€”remains brand-neutral)
2. **No veto power** (pharma cannot block Foundation contentâ€”even if critical of company)
3. **Patient-first messaging** (Foundation advocates for patientsâ€”even if conflicts with company interest, e.g., drug pricing)

**Examples in Practice**:

**Scenario 1: Drug Pricing Advocacy**

- Foundation advocates for lower augmentation therapy costs (testifies to Congressâ€”"$150K/year is unaffordable")
- Grifols/CSL/Takeda may disagree (pricing pressure threatens profits)
- **Foundation's Stance**: Advocate anyway (patient interest > company interestâ€”companies can discontinue grant if they want, but Foundation won't be silenced)

**Scenario 2: Comparative Effectiveness**

- Foundation publishes registry study: "All augmentation brands equally effective" (no significant difference in outcomes)
- Grifols (largest funder) may prefer Foundation promote Prolastin as "superior" (justify premium price)
- **Foundation's Stance**: Publish truth (data shows no differenceâ€”Foundation reports accurately, helps patients make informed decisions)

**Scenario 3: Alternative Therapy Promotion**

- Foundation promotes gene therapy (future alternative to augmentationâ€”threatens augmentation market)
- Augmentation manufacturers may want Foundation to downplay gene therapy (protect current revenue)
- **Foundation's Stance**: Promote gene therapy (patient benefitâ€”potential cure vs. lifelong infusions, Foundation prioritizes best outcome for patients)

---

### Diversified Revenue

**Why It Matters**:

- Dependence = vulnerability (if pharma = 80% of budget, companies control Foundationâ€”threaten to withdraw funding, Foundation must comply)
- Diversification = independence (if pharma = 30%, losing one company = manageableâ€”Foundation negotiates from strength, not desperation)

**Foundation's Target**:

- Individuals: 40-50% of revenue (major gifts, mid-level, annual fundâ€”broad base)
- Events: 15-20% (Walk, Gala, Virtualâ€”community engagement)
- Foundations/grants: 10-15% (NIH, private foundationsâ€”non-pharma)
- Pharma/corporate: 20-30% (never exceed 30%â€”maintain independence)
- Other: 5-10% (planned giving, endowment, miscellaneous)

---

## Contract Negotiation Guidelines

### Key Terms to Negotiate

**1. Grant Amount & Duration**

- **Ask high** (companies have budgetâ€”Foundation should request top tier)
- **Multi-year preferred** (3-year commitmentâ€”predictable revenue, reduces annual fundraising burden)
- **Escalation clause** (2-3% annual increaseâ€”keeps pace with inflation)

**Example Term**: "$500K/year for 3 years, with 3% escalation in Years 2-3 ($500K Y1, $515K Y2, $530K Y3)"

---

**2. Restriction Level**

- **Unrestricted strongly preferred** (maximum flexibilityâ€”Foundation decides use)
- **If restricted, broad purpose** (e.g., "patient education" vs. "travel to conferences"â€”avoid overly narrow restrictions)
- **Overhead allocation** (15% of grant can go to admin/fundraisingâ€”covers Foundation's true costs)

**Example Term**: "Unrestricted grant for general support of patient programs, with up to 15% allocated to administrative costs."

---

**3. Recognition vs. Endorsement**

- **Recognition acceptable** (Foundation acknowledges grantâ€”"Thank you to [Company]," logo on website, event materials)
- **Endorsement prohibited** (Foundation never says "We recommend [Company's drug]"â€”maintains neutrality)

**Example Term**: "Foundation will acknowledge [Company] as Platinum Sponsor on website, in Annual Report, and at events. Foundation will not endorse, recommend, or promote [Company's] products."

---

**4. Publication & Data Rights**

- **Foundation owns data** (if research fundedâ€”Foundation controls publication, company cannot block)
- **Company review allowed** (company can review manuscriptsâ€”fact-check, ensure accuracy, not to suppress unfavorable results)
- **IP split if applicable** (if research leads to patentâ€”negotiate upfront, typically 50/50 or Foundation-majority)

**Example Term**: "Foundation retains ownership of all data and right to publish results. [Company] may review manuscripts for factual accuracy, with 30 days' notice. [Company] may not delay or block publication based on unfavorable results."

---

**5. Termination Clause**

- **Mutual termination** (either party can exit with 90 days' noticeâ€”protects both)
- **No clawback** (company cannot demand refund if relationship endsâ€”Foundation can plan with confidence)

**Example Term**: "Either party may terminate this agreement with 90 days' written notice. Funds already disbursed to Foundation are non-refundable."

---

### Red Flags (Deal-Breakers)

**âŒ Exclusive relationship** ("Foundation cannot accept grants from competing companies"â€”limits diversification, unacceptable)

**âŒ Product endorsement required** ("Foundation must promote [Drug] in patient materials"â€”violates neutrality, unacceptable)

**âŒ Veto power over content** ("Company approves all Foundation content before publication"â€”violates editorial independence, unacceptable)

**âŒ Contingent on sales** ("Grant paid only if [Drug] sales increase"â€”creates conflict of interest, unacceptable)

**âŒ Patient data access** ("Company gets identifiable patient data from registry"â€”violates privacy, unacceptable, de-identified aggregate data only)

---

## Partnership Activation

### Beyond the Check: Maximizing Partnership Value

**Joint Activities** (Enhance relationship beyond grant):

**1. Patient Education Webinars** (Co-host with company):

- Foundation invites patients (500-1,000 attendeesâ€”Foundation's reach)
- Company provides speaker (medical science liaisonâ€”explain therapy, answer questions)
- **Value to Foundation**: Expert content (company employees are expertsâ€”save Foundation from hiring speaker)
- **Value to Company**: Direct patient engagement (brand visibility, educate patients about therapy options)
- **Boundaries**: No product promotion (education onlyâ€”"Here's how augmentation therapy works," not "Buy Prolastin")

---

**2. Booth at Foundation Events**:

- Company sponsors Walk or Conference (booth in health fair, exhibit hall)
- Company staff distribute materials (educational brochures, not sales pitchesâ€”AATD info, testing resources)
- **Value to Foundation**: Enhanced event (more exhibitors = better experience for attendees)
- **Value to Company**: Face-to-face with patients (build relationships, answer questions, brand presence)
- **Boundaries**: No hard sell (education/support focusâ€”not "Switch to our brand," patients turned off by sales tactics)

---

**3. Joint Research Proposals**:

- Foundation + company submit joint grant applications (to NIH, foundationsâ€”co-applicants)
- Leverage both parties' strengths (Foundation = patient access, company = scientific expertise)
- **Value to Foundation**: Larger grants (NIH more likely to fund if industry partnerâ€”signals feasibility)
- **Value to Company**: Academic credibility (Foundation collaboration = neutral researcher, not commercial study)

---

**4. Advisory Board Participation**:

- Company representative sits on Foundation's Scientific Advisory Board (provide industry perspectiveâ€”what's in pipeline? what's feasible?)
- **Value to Foundation**: Industry insights (understand what companies are developingâ€”shape Foundation research priorities)
- **Value to Company**: Shape research agenda (influence what Foundation fundsâ€”align with company interests, but Foundation maintains veto)
- **Boundaries**: Non-voting seat (advisory onlyâ€”company doesn't control funding decisions)

---

## Success Metrics

### Partnership Performance Metrics

**Revenue Metrics**:

- Total pharma revenue: $500K (Y1) â†’ $2.5M (Y5)
- # of pharma partners: 3 (Y1) â†’ 8-10 (Y5)
- Multi-year partnerships: 50% by Y3 (predictable revenueâ€”less annual fundraising churn)

**Relationship Metrics**:

- Renewal rate: 80%+ (most partners renew annuallyâ€”indicates satisfaction)
- Escalation rate: 30% of partners increase grant size year-over-year (deepen commitment)
- Referrals: Partners introduce Foundation to other companies (network effectâ€”CSL intro to diagnostics company, collaboration opportunity)

**Independence Metrics**:

- Pharma as % of budget: <35% (Y1-Y5â€”never over-reliant)
- # of times Foundation advocated contrary to pharma interest: Track annually (shows independenceâ€”willing to speak truth even if upsets funder)

**Impact Metrics** (Foundation Programs Enabled by Pharma Funding):

- Patients served: 500 (Y1, $500K pharma funding) â†’ 5,000 (Y5, $2.5M pharma funding)
- Research funded: $100K (Y1) â†’ $1M (Y5â€”pharma co-funding accelerates)
- Clinical trials accelerated: 1 (Y1) â†’ 5 (Y5â€”pharma + Foundation collaborations)

---

## Risk Management

### Potential Risks & Mitigation Strategies

**Risk 1: Perceived Conflict of Interest**

- **Scenario**: Patients believe Foundation is "pharma-funded puppet," lose trust
- **Mitigation**:
  - Transparency (disclose all pharma fundingâ€”Annual Report, website, no secrets)
  - Diversified revenue (pharma <35%â€”demonstrate independence)
  - Patient advisory board (patients review pharma partnershipsâ€”veto if concern)

---

**Risk 2: Actual Conflict of Interest**

- **Scenario**: Foundation must advocate against pharma interest (e.g., drug pricing), company withdraws funding, budget crisis
- **Mitigation**:
  - Diversified revenue (losing one company = 5-10% of budgetâ€”painful but manageable)
  - Reserve fund (6 months operating expenses savedâ€”bridge gap if funding lost)
  - Transparent terms (contracts allow terminationâ€”both parties know risks upfront)

---

**Risk 3: Mission Drift**

- **Scenario**: Foundation prioritizes pharma-friendly activities (education, support) over uncomfortable advocacy (pricing, accessâ€”neglect advocacy to avoid upsetting funders)
- **Mitigation**:
  - Board oversight (Board annually reviews advocacy agendaâ€”ensure Foundation speaks up)
  - Patient input (patients identify Foundation's advocacy prioritiesâ€”not pharma)
  - Public commitments (Foundation publicly commits to specific advocacy goalsâ€”e.g., "Reduce augmentation costs"â€”accountability)

---

**Risk 4: Regulatory Scrutiny**

- **Scenario**: IRS or state AG investigates Foundation-pharma relationship (concerned Foundation is marketing arm of company, not true charity)
- **Mitigation**:
  - Legal review (contracts reviewed by nonprofit attorneyâ€”ensure compliance)
  - Arm's length transactions (fair market value for servicesâ€”no sweetheart deals)
  - Document charitable purpose (all pharma grants support tax-exempt missionâ€”patient education, research, not product promotion)

---

## Implementation Timeline

### Year 1: Foundation Launch

**Q1: Build Business Case**

- Develop partnership deck (presentation for pharma companiesâ€”Foundation overview, value proposition, partnership tiers)
- Identify contacts (BD teams at Grifols, CSL, Takedaâ€”leverage board connections, advisors)

**Q2: Initiate Conversations**

- Meet with Grifols, CSL, Takeda (in-person or Zoomâ€”present Foundation, explore partnership)
- Proposal submission (customize pitchâ€”each company's goals, competitive positioning)

**Q3: Negotiate & Close**

- Finalize contracts (legal review, negotiate termsâ€”aim for unrestricted grants)
- Announce partnerships (press releaseâ€”"Grifols Supports Mark Egly Foundation"â€”donor stewardship, public transparency)

**Q4: Deliver Value**

- Launch funded programs (use pharma grantsâ€”patient navigation, support groups, etc.)
- Stewardship (quarterly updates to pharma partnersâ€”show impact, build relationship)

---

### Year 2-3: Expand Portfolio

**Year 2**:

- Add 2-3 new partners (gene therapy companiesâ€”AGTC, Beam, expand beyond augmentation)
- Renew Year 1 partners (80%+ renewalâ€”deepen relationships, increase grant size)

**Year 3**:

- Add diagnostics partnerships (Invitae, Abbottâ€”expand beyond therapy manufacturers)
- Establish patient assistance fund (co-pay supportâ€”$1M-$2M funded by pharma, Foundation-administered)

---

### Year 4-5: Optimize Portfolio

**Year 4-5**:

- Mature partnerships (multi-year agreementsâ€”3-year terms reduce annual negotiation burden)
- Joint research portfolio ($1M-$2M co-funded studiesâ€”real-world evidence, clinical trials)
- Revenue stabilizes ($2M-$3M/yearâ€”predictable, diversified, sustainable)

---

## Summary

**Pharma Partnerships = Strategic Alliances, Not Faustian Bargains**:

- âœ… **Revenue**: $2M-$3M/year by Year 5 (funds patient programs, research, advocacyâ€”accelerates mission)
- âœ… **Independence Maintained**: <35% of budget, diversified partners, editorial control (patient-first always)
- âœ… **Transparency**: All pharma funding disclosed (Annual Report, websiteâ€”patients trust Foundation)
- âœ… **Mutual Benefit**: Pharma gains market access, Foundation gains resources (aligned interestsâ€”both want more patients diagnosed, treated)

**5-Year Vision**: 8-10 pharma partners (augmentation manufacturers, gene therapy developers, diagnostics companies), $2.5M annual revenue, 80%+ renewal rate, zero compromises on patient advocacy

**"Work with industry, never for industry. Patient interests always come first."**

---

**Explore Partnership Opportunities**

**Mark Egly Foundation Corporate Partnerships**
ğŸ“§ Email: partnerships@markeglyfoundation.org
ğŸ“ Phone: (XXX) XXX-XXXX
ğŸŒ Website: MarkEglyFoundation.org/Partners

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Partners in progress, guardians of patients."_

**â€” Mark Egly Foundation**
